share hit m drug suspension share elan biogen idec plunge monday firm suspend sale new multiple sclerosis drug tysabri patient death us new york stock exchange share irelandbased elan lose 70 us partner biogen idec 43 firm take action death central nervous system disease suspect case condition case cite involve use tysabri avonex biogen idecs exist multiple sclerosis drug company say report rare condition progressive multifocal leukoencephalopathy pml patient take either tysabri avonex alone tysabri approve use us last november widely tipped become world lead multiple sclerosis treatment company will work clinical investigator evaluate tysabritreated patient will consult lead expert understand possible risk pml two firm say statement outcome evaluation will use determine possible reinitiation dose clinical trial future commercial availability analyst believe product provide new growth opportunity biogen idec face increase competition rival avonex elan big firm irish stock exchange also expect receive boost new product inquiry elan account 2002 brought group close bankruptcy firm rebuild since share price increase almost fourfold last year value company tysabri say ian hunter goodbody stockbroker dublin now question mark elan finish 1890 8 biogen fell 2863 3865 share uk pharmaceutical firm phytopharm close 1984 1515 penny london stock exchange monday say partner set pull deal experimental alzheimers disease treatment phytopharm say japan yamanouchi pharmaceutical likely end licensing agreement prompt analyst raise question level future cash reserve 